A Phase 1 interventional study of YHP2508B and YHR2602 in Healthy Subjects (HS), sponsored by Yuhan Corporation. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 54 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Yuhan Corporation · Phase 1, Interventional, and Treatment
An open-label, randomized, fasting, single-dose, oral administration, 2-sequence, 4-period, replicate crossover study to evaluate bioequivalence between YHP2508B and YHR2602 in healthy subjects.
44 healthy subjects will be randomized to one of 2 groups in the same ration.
Subjects in group 1 will be administered "YHR2602" and "YHP2508B" by crossover design on periods 1 to 4.
Subjects in group 2 will be administered "YHP2508C" and "YHR2603" by crossover design on periods 1 to 4.
Yuhan Corporation is the lead sponsor of 110 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
22 subjects, Cross-over, Single dose YHR2602 on period 1 and 3, Single dose of YHP2508B on period 2 and 4.
Drug: YHP2508B · Drug: YHR2602
22 subjects, Cross-over, Single dose YHP2508B on period 1 and 3, Single dose of YHR2602 on period 2 and 4.
Drug: YHP2508B · Drug: YHR2602
Test drug
Comparator drug
Area under the plasma drug concentration-time curve [AUCt]
Area under the plasma drug concentration-time curve \[AUCt\] of Amlodipine, Telmisartan \& Chlorthalidone
Time frame: 0-72 hours
Maximum plasma concentration [Cmax]
Maximum plasma concentration \[Cmax\] of Amlodipine, Telmisartan \& Chlorthalidone
Time frame: 0-72 hours
Area under the plasma drug concentration -time curve from 0 to infinity [AUCinf]
Area under the plasma drug concentration-time curve from time 0 to infinity \[AUCinf\] of Amlodipine, Telmisartan \& Chlothalidone
Time frame: 0-72 hours
Area under the plasma drug concentration-time curve/Area under the plasma drug concentration-time curve from time 0 to infinity [AUCt/AUCinf]
Area under the plasma drug concentration-time curve/Area under the plasma drug concentration-time curve from time 0 to infinity \[AUCt/AUCinf\] of Amlodipine, Telmisartan \& Chlothalidone
Time frame: 0-72 hours
Time of peak concentration [Tmax]
Time of peak concentration \[Tmax\] of Amlodipine, Telmisartan \& Chlorthalidone
Time frame: 0-72 hours
Terminal phase of half-life [t1/2]
Terminal phase of half-life \[t1/2\] of Amlodipine, Telmisartan \& Chlorthalidone
Time frame: 0-72 hours
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.